Home > Diabetic Macular Oedema
  • FILTER YOUR SEARCH
    Content Type:
  • Diabetic Macular Oedema

    An Introduction to Diabetic Macular Oedema

    The introduction of anti-vascular endothelial growth factor (anti-VEGF) therapies changed the standard of care for patients with diabetic macular oedema, however, the need for longer-acting medications and novel therapeutic targets still exist. Looking to the future, new treatments targeting multiple pathways are currently under investigation.

    Browse the content below, to see leading experts discuss the latest data in video interviews and short articles from our conference hub. You can also view the selection of peer-reviewed articles from our journals. If you’re looking to learn more about the impact of these developments on patient outcomes, our educational activities are a great resource.

    Our supporting partners do not constitute an endorsement of the content on this page.

    Diabetic Macular Oedema Content

    Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greyarrow-right-orangearrow-right-whitearrow-right-blueavatarcalendarchevron-down crosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmenumore_dots padlock person play_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar